May 5, 2026
Johnson & Johnson's IBD Therapy Fails to Meet Primary Endpoint in Clinical Trial
Johnson & Johnson's closely watched inflammatory bowel disease therapy failed to show statistically significant improvement in patients during clinical trials, representing a setback for the pharmaceutical giant's gastroenterology pipeline.
1 source
00